Schroder Investment Management Group Sells 158,817 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Schroder Investment Management Group lessened its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 86.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,615 shares of the company's stock after selling 158,817 shares during the period. Schroder Investment Management Group's holdings in Akero Therapeutics were worth $716,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AlphaQuest LLC increased its holdings in shares of Akero Therapeutics by 32,588.0% in the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after acquiring an additional 8,147 shares during the last quarter. Sei Investments Co. bought a new stake in shares of Akero Therapeutics in the 4th quarter worth approximately $303,000. KLP Kapitalforvaltning AS acquired a new stake in Akero Therapeutics during the 4th quarter worth about $306,000. XTX Topco Ltd acquired a new stake in shares of Akero Therapeutics in the third quarter worth $308,000. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Akero Therapeutics during the 4th quarter valued at $320,000.

Insider Buying and Selling at Akero Therapeutics

In other news, Director G. Walmsley Graham purchased 200,000 shares of the business's stock in a transaction dated Thursday, January 30th. The stock was bought at an average price of $48.00 per share, with a total value of $9,600,000.00. Following the acquisition, the director now owns 1,000,000 shares in the company, valued at approximately $48,000,000. The trade was a 25.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Cheng sold 30,000 shares of the business's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $35.23, for a total value of $1,056,900.00. Following the transaction, the chief executive officer now directly owns 624,324 shares of the company's stock, valued at $21,994,934.52. This trade represents a 4.58 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders acquired 341,309 shares of company stock valued at $15,863,578 and sold 278,385 shares valued at $13,345,929. Insiders own 7.94% of the company's stock.

Remove Ads

Akero Therapeutics Stock Performance

AKRO stock traded up $0.85 during trading hours on Friday, reaching $35.67. The stock had a trading volume of 814,604 shares, compared to its average volume of 857,773. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The stock has a market capitalization of $2.84 billion, a PE ratio of -9.51 and a beta of -0.18. The stock has a 50-day simple moving average of $44.86 and a 200 day simple moving average of $35.86.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on AKRO shares. Bank of America upgraded Akero Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. UBS Group lifted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a report on Friday, January 31st. Citigroup raised their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. HC Wainwright raised their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $76.29.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.